episode 914: COVID-19 clinical update #121 with Dr. Daniel Griffin
In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Age as a risk factor for severe disease (NY Times)
- Omicron boosters for the fall (NPR)
- Pediatric infection and antibody seroprevalence in Arkansas (PIDS)
- All-cause US maternal mortality during pandemic (JAMA)
- Effect of 2-week interruption in methotrexate treatment (The Lancet)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- PAXLOVID drug interaction checker (IDSA)
- Contribute to FIMRC fundraiser at PWB 35:42
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 914
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv